Literature DB >> 32410761

Cardiac valves: Another "Disaster-hit area" of COVID-19 patients?

Xiaoyong Li1, Sha Yu2.   

Abstract

Entities:  

Year:  2020        PMID: 32410761      PMCID: PMC7221407          DOI: 10.1016/j.hrtlng.2020.05.004

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


× No keyword cloud information.
To the Editor, Coronavirus disease 2019 (COVID-19), characterized by acute respiratory failure and multiple organs damages, has been becoming a pandemic disease around the world since December 2019. The pathogenthat induced COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . , According the data from the World Health Organization (WHO), by 27 April 2020, there have been 2883,603 confirmed cases of COVID-19 with 198,842 deaths. Although respiratory failure is the main clinical character of COVID-19 patients, quite a few patients developed cardiovascular diseases, such as cardiac arrest, myocarditis and arrhythmia. However, the effect of COVID-19 on cardiac valves, the hinge during the process of blood flow, has not been fully identified pathologically and functionally. Therefore, it is a significant question that whether the SARS-CoV-2 virus could attack the cardiac valves. Angiotensin-converting enzyme 2 (ACE2) has been identified as the receptor for SARS-CoV-2, mediating its entry to host cells. Except in the lung, ACE2 generally expresses in alimentary canal, kidney, testis and heart. With regards to the heart, expression of ACE2 in myocardium and associated myocardial pathology have been wildly reported. Additionally, ACE2 was also detected in cardiac valves, specifically aortic valve in human, and associated with the process of aortic valve stenosis. Detected by immunostaining, ACE2 located at stromal fibroblasts, mainly in spongiosa layer. Stenotic valves showed decrescent extensiveness of ACE2 and abnormal expression of ACE2 in macrophages and myofibroblasts surrounding neovessels. Compared with normal valves, downregulated ACE2 in stenotic valves was determined by RT-PCR. Downregulation of ACE2/Angiotensin-(1–7)/Mas receptor axis may promote fibrosis, proliferation and inflammation in cardiac valves, causing valvular sclerosis and hemodynamic disorder finally. Considering the complex and dynamic changes of SARS-CoV-2 in infected soma, the ACE2+ cells in cardiac valves could be attacked by SARS-CoV-2 directly. Dysfunction of these cells could induce pathological procedure in cardiac valves and obstruct regular blood flow consequently. Formation of hyaline thrombus in small vessels, degeneration and necrosis of parenchymal cells and other pathological changes of chronic diseases could be caused by cytokine storm. , Cytokine storm, another lethal pathology in COVID-19 featured with IL6, IL10 and TNF-α, may play an important role in the regression and maintenance of valvular lesions. , Cardiac valves disease is usually slow-moving and often requires a long journey from the “ignition” of pathology to related clinical symptoms. As the direct attack mediated by ACE2+ cells and indirect attack from cytokine storm, the damages in cardiac valves induced by SARS-CoV-2 could not be ignored. Thus, we emphatically advise that the survivors of COVID-19, especially those with acquired heart disease, should be examined for cardiac function periodically after recovery. The expression and biological function of ACE2 in cardiac valves should be identified further and cohort studies about cardiac valves targeting infected populations may provide guidance to public health policy.

Declarations

Ethical statement

The article doesn't contain the participation of any human being and animal.

Original publication

This work described has not been published previously and it is not under consideration for publication elsewhere.

Patient consent

Not applicable

Source of support

None

Author contributions

Xiaoyong Li: Writing-original draft, Sha Yu: Writing-review & editing, Sha Yu designed this project and Xiaoyong Li drafted this manuscript.

Declaration of Competing Interest

These authors declare no conflict of interest. All the authors have read and approved this manuscript.
  7 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis.

Authors:  Tuomas Peltonen; Juha Näpänkangas; Pasi Ohtonen; Jani Aro; Jenni Peltonen; Ylermi Soini; Tatu Juvonen; Jari Satta; Heikki Ruskoaho; Panu Taskinen
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

3.  Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions.

Authors:  Luiza Guilherme; Patricia Cury; Lea M F Demarchi; Verônica Coelho; Lúcia Abel; Ana P Lopez; Sandra Emiko Oshiro; Selma Aliotti; Edécio Cunha-Neto; Pablo M A Pomerantzeff; Ana C Tanaka; Jorge Kalil
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

4.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.

Authors:  Han Zhu; June-Wha Rhee; Paul Cheng; Sarah Waliany; Amy Chang; Ronald M Witteles; Holden Maecker; Mark M Davis; Patricia K Nguyen; Sean M Wu
Journal:  Curr Cardiol Rep       Date:  2020-04-21       Impact factor: 2.931

6.  COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.

Authors:  Toshio Hirano; Masaaki Murakami
Journal:  Immunity       Date:  2020-04-22       Impact factor: 31.745

7.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

  7 in total
  5 in total

1.  Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging.

Authors:  Eugenio Picano; Quirino Ciampi; Lauro Cortigiani; Adelaide M Arruda-Olson; Clarissa Borguezan-Daros; José Luis de Castro E Silva Pretto; Rosangela Cocchia; Eduardo Bossone; Elisa Merli; Garvan C Kane; Albert Varga; Gergely Agoston; Maria Chiara Scali; Doralisa Morrone; Iana Simova; Martina Samardjieva; Alla Boshchenko; Tamara Ryabova; Alexander Vrublevsky; Attila Palinkas; Eszter D Palinkas; Robert Sepp; Marco A R Torres; Hector R Villarraga; Tamara Kovačević Preradović; Rodolfo Citro; Miguel Amor; Hugo Mosto; Michael Salamè; Paul Leeson; Cristina Mangia; Nicola Gaibazzi; Domenico Tuttolomondo; Costantina Prota; Jesus Peteiro; Caroline M Van De Heyning; Antonello D'Andrea; Fausto Rigo; Aleksandra Nikolic; Miodrag Ostojic; Jorge Lowenstein; Rosina Arbucci; Diego M Lowenstein Haber; Pablo M Merlo; Karina Wierzbowska-Drabik; Jaroslaw D Kasprzak; Maciej Haberka; Ana Cristina Camarozano; Nithima Ratanasit; Fabio Mori; Maria Grazia D'Alfonso; Luigi Tassetti; Alessandra Milazzo; Iacopo Olivotto; Alberto Marchi; Hugo Rodriguez-Zanella; Angela Zagatina; Ratnasari Padang; Milica Dekleva; Ana Djordievic-Dikic; Nikola Boskovic; Milorad Tesic; Vojislav Giga; Branko Beleslin; Giovanni Di Salvo; Valentina Lorenzoni; Matteo Cameli; Giulia Elena Mandoli; Tonino Bombardini; Pio Caso; Jelena Celutkiene; Andrea Barbieri; Giovanni Benfari; Ylenia Bartolacelli; Alessandro Malagoli; Francesca Bursi; Francesca Mantovani; Bruno Villari; Antonello Russo; Michele De Nes; Clara Carpeggiani; Ines Monte; Federica Re; Carlos Cotrim; Giuseppe Bilardo; Ariel K Saad; Arnas Karuzas; Dovydas Matuliauskas; Paolo Colonna; Francesco Antonini-Canterin; Mauro Pepi; Patricia A Pellikka
Journal:  J Clin Med       Date:  2021-08-17       Impact factor: 4.964

Review 2.  COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.

Authors:  Yasar Sattar; Waqas Ullah; Hiba Rauf; Hafeez Ul Hassan Virk; Sunita Yadav; Medhat Chowdhury; Michael Connerney; Sahil Mamtani; Mohit Pahuja; Raj D Patel; Tanveer Mir; Talal Almas; Homam Moussa Pacha; M Chadi Alraies
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-14

Review 3.  Cardiovascular complications in the Post-Acute COVID-19 syndrome (PACS).

Authors:  Sheref A Elseidy; Ahmed K Awad; Monica Vorla; Amina Fatima; Merihan A Elbadawy; Debvarsha Mandal; Tamam Mohamad
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-28

4.  Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).

Authors:  Jonathan H Whiteson; Alba Azola; John T Barry; Matthew N Bartels; Svetlana Blitshteyn; Talya K Fleming; Mark D McCauley; Jacqueline D Neal; Jayasree Pillarisetti; Sarah Sampsel; Julie K Silver; Carmen M Terzic; Jenna Tosto; Monica Verduzco-Gutierrez; David Putrino
Journal:  PM R       Date:  2022-07-13       Impact factor: 2.218

5.  Acute Kidney Injury and Early Predictive Factors in COVID-19 Patients.

Authors:  Jiaye Liu; Tingyan Wang; Qingxian Cai; Deliang Huang; Liqin Sun; Qing He; Fu-Sheng Wang; Jun Chen
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.